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Introduction 
In orthotopic liver transplantation (OLT) hyperfibrinolysis is most prominent im-
mediately before reperfusion — characterized by increased formation of plasmin-
antiplasmin (PAP) complexes — and enhanced Prothrombin activation thereafter — 
characterized by rising thrombin-antithrombin III (TAT) complexes — have been 
described and accepted to occur regularly [1—4]. Paradoxically, the increased 
Prothrombin activation after revascularisation of the graft may be paralleled in the 
clinical Situation by oozing in the Operation field, a Situation often observed during 
DIC. 
We investigated parameters of coagulation, e.g., fibrinogen, factor XIII (F XIII), 
antithrombin III (AT III), free protein S antigen (protein S) and TAT, parameters of 
fibrinolysis, e.g., tissue-type Plasminogen activator (t-PA), urokinase-type Plasmino-
gen activator (u-PA), Plasminogen activator inhibitor (PAI), Cl-inhibitor and PAP, 
mediators of leucocyte activation, e.g., tumor necrosis factor alpha (TNF-a), 
neopterin, cathepsin B, neutrophile elastase in complex with protease inhibitor (EPI), 
platelet count and platelet aggregability as well as the endothelium-derived soluble 
thrombomodulin (sTM)) in the course of 20 consecutive liver transplantations in order 
to understand more clearly the pathophysiological changes occurring during OLT, 
especially with reperfusion of the graft liver. 
The impaired hemostasis due to preexisting liver failure is aggravated during OLT 
in these patients, resulting in a DIC-like constellation that may be considered to 
represent a human model for studying DIC. 
*Address for correspondence: Professor Dr. med. Hanno Riess, Universitätsklinikum Rudolf Virchow, 
Augustenburger Platz 1, 13344 Berlin, Germany. 
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Materials and Methods 
OLT was carried out by established surgical techniques using a veno-venous bypass 
[5]. Packed red blood cells (RBC) and fresh frozen plasma (FFP) but neither platelets 
nor concentrates of hemostatic factors were substituted to compensate for intraopera-
tive blood loss. Patients received a median of 8.6 units (ränge: 2—26) of RBC and 7.8 
units FFP (ränge: 2—28). Most of these transfusions were given during the pre-
anhepatic and anhepatic phases. 
Blood samples were taken from the arterial line, after induction of anaesthesia and 
before Operation statt <1>, 5 min before <2> and 10 min after <3> the beginning of 
the anhepatic stage. Further samples were collected 5 min before reperfusion <4>, as 
well as 5 min <5>, 15 min <6> and 60 min afterwards. 
The following parameters were measured: protein C activity, protein S Ag (all: 
Boehringer, Mannheim, Germany); AT III activity, Cl-inhibitor activity, TAT 
complexes, F XIII activity (all: Behringwerke AG, Marburg, Germany), fibrinogen 
according to Clauss (Hoffmann-LaRoche, Basel, Switzerland), t-PA and PAI activities 
(both Chromogenix, Stockholm, Sweden), PAP complexes (Technoclone, Vienna, 
Austria), sTM Ag, (Stago, Paris, France). 
Cathepsin B was measured by its enzymatic activity against the aminopeptidase 
Substrate Z-Phe-Arg-NMec [6]. Elastase was estimated in complex with arproteinase 
inhibitor according to Neumann [7]. Neopterin was estimated by RIA (Henning, 
Berlin, Germany) and TNF-a by IRMA (Medgenix Diagnostics, Fleurus, Belgium). 
Urokinase-type Plasminogen activator (u-PA) antigen was measured by ELISA and 
u-PA activity were measured by BIA as previously described [8]. 
Platelet rieh plasma (PRP) was obtained by centrifugation for 6 min at 600 U/min. 
To obtain platelet poor plasma (PPP) another centrifugation for 20 min at 3,000 
U/min was added. Platelet counts in PRP were adjusted to 200,000 platelets/ul or 
PRP with lower platelet counts was directly used in thrombocytopenic patients. In an 
individual series this platelet concentration was reobtained by diluting with PPP or 
by a further "concentrating" low speed centrifugation in order to eliminate different 
aggregating capacities caused by varying platelet counts. Platelet aggregation 
according to Born [9] registered by an automated platelet aggregation tracer System 
(APACT, Labor GmbH, Ahrensburg, Germany) was induced by collagen (final con-
centration 1.0 ug/ml), ADP (2 jnmol/1) or ristocetin (1.2 mg/ml). Before each 
determination platelet aggregation was calibrated with PRP and PPP. Platelet 
aggregation was determined by measuring the maximal amplitude. 
Results in the figures are given as medians and the non-parametric Wilcoxon 
signed-ranks test was used to evaluate differences of levels between the timepoints; 
values of p < 0.5 were considered to be significant. 
Results 
Most of the results obtained have been reported and discussed in detail [2,10—14]. 
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PAP, t-PA, PAI anhepatic phase tcu-PA. d- inhibi tor 
Operation Start reperfusion 
F i g . L Parameters of fibrinolysis (t-PA, PAI, Cl-inhibitor activities, two-chain u-PA (active form of u-PA, 
tcu-PA) and PAP complexes) during OLT. 
Here a comprehensive review focussing on the changes after revascularisation of the 
liver graft will be given. 
The evaluation of parameters of fibrinolysis (Fig. 1) showed a decrease in t-PA, 
u-PA and PAP complexes after reperfusion preceded by peak levels at the end of the 
anhepatic phase. The Cl-inhibitor levels significantly decreased with reperfusion 
whereas the PAI levels demonstrated a highly significant rise. 
Looking at parameters of coagulation (Fig. 2) a highly significant increase in TAT 
complexes was accompanied by decreases in the levels of fibrinogen, AT III and 
protein S, whereas protein C activity levels were rising towards the end of the 
Operation. The F XIII levels demonstrated a short insignificant increase in the very 
early reperfusion phase followed by a significant decrease 10 min later. 
With regard to the behaviour of platelets (Fig. 3) a significant decrease is seen in 
platelet count as well as in collagen-, ADP- and ristocetin-induced platelet ag-
gregability with reperfusion. 
Mediators of leucocyte activation, TNF-a, EPI complexes, cathepsin B, and 
neopterin increase clearly after reperfusion (Fig. 4). 
Looking at endothelium-derived parameters (Fig. 5) we observed a significant 
increase of sTM. 
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Operation Start reperfusion 
neo.(nmol/l), TNF (pg/ml) EPKng/ml), cathepsin B (mU/l) 
Operation start 
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Discussion 
During OLT a strongly enhanced Prothrombin activation paralleled by an increased 
consumption of inhibitors and fibrinogen can be demonstrated after revascularisation 
of the graft. The thrombin formation is reflected in the increase in TAT and in the 
enhanced formation of fibrin monomers as well as d-dimers (not shown here, [3,12]). 
Furthermore the thrombin formation may play an important role in the impairment 
of platelet count and function. These data strongly favour that there is a DIC-like 
Situation regularly occurring during reperfusion thereby confirming previous 
investigations [1—4]. 
The rise of protein C is probably reflecting an early synthesis by the graft liver. 
The increase in F XIII levels in the very early reperfusion phase is explained by 
hepatic release as elevated F XIII levels are seen as well in the perfusate [14]. 
Furthermore, we tried to evaluate the pathomechanisms leading to increased Pro-
thrombin activation. The extrinsic and intrinsic fibrinolytic Systems are activated in 
the anhepatic phase — probably by contact activation in the veno-venous bypass and 
by reduced activator clearance — reaching maxima at its end. Hyperfibrinolysis as 
reflected in thromboelastography [2] may play an important role in influencing the 
anhepatic blood loss and may favour the generation of weak clots in the Operation 
field. After revascularisation of the graft liver Plasminogen activators can be cleared 
out of the systemic circulation. PAI may be released by (thrombin-) stimulated 
platelets and in addition PAI activity steeply rises due to its acute-phase properties. 
Thereby decreases in t-PA and u-PA activities are explained. The decrease of C l -
inhibitor is caused by consumption during the anhepatic phase. 
However, no correlation could be demonstrated between parameters of increased 
fibrinolysis and parameters of increased thrombin formation, making the possibility 
unlikely, that the observed "DIC" is secondary to hyperfibrinolysis. 
In parallel with increased Prothrombin activation in the reperfusion phase a 
significant decrease in platelet count and platelet aggregability and an increase in 
leucocytic mediators could be observed suggesting platelet and leucocyte activation, 
as had been described during DIC [6]. In addition, increasing levels of sTM in the 
reperfusion phase suggest endothelial damage. Endothelial damage is able to induce 
both, platelet and leucocyte activation and vice versa. Mediators released upon 
leucocyte activation like elastase may induce thrombin activation, degrade AT III and 
may thus induce a DIC-like State [15] as well as modulate platelet function [16]. 
TNF-a released from leucocytes on the other hand alters the endothelium [17]. 
Furthermore mediators released from leucocytes in addition to those measured exhibit 
a variety of degrading properties. The oozing observed exclusively in the reperfusion 
phase may thereby result from the proteolysis of non-resistant clots formed during the 
F i g . 2. (Facing page, top). Parameters of coagulation (fibrinogen, F XIII, A T III, T A T complexes, free 
protein S antigen) during OLT. 
F i g . 3. (Facing page, bottom). Mediators of leucocyte activation (TNF-a, neoptein, cathepsin B, EPI 
complexes) during OLT. 
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F i g . 6. Suggested pathomechanism leading to oozing and increased blood loss during the reperfusion 
phase in orthotopic liver transplantation. 
anhepatic phase when systemic signs of hyperfibrinolysis are present. On the other 
hand, locally restricted reactive ("secondary") hyperfibrinolysis cannot be ruled out 
by our investigations. This view is supported by the protective effect of aprotinin, an 
antifibrinolytic protease inhibitor, on oozing in OLT [18]. 
Comparative studies in patients undergoing OLTs and heterotopic liver transplanta-
tion [19] stress the importance of the diseased host liver preventing the deterioration 
in hemostasis observed during the anhepatic and reperfusion phases. 
Facing the question raised in the headline of this article we are convinced that 
F i g . 4. (Facing page, top). Platelet count and parameters of platelet aggregability (ADP-, collagen- and 
ristocetin-induced platelet aggregability) measured by maximal amplitude (MA, see text) during OLT. 
Fig. 5. (Facing page, bottom). Soluble thrombomodulin (sTM) as endothelial-derived parameter during 
O L T . 
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hemostasis in OLT is a valuable model in humans to study DIC development because 
the changes described are regularly observed, though differently pronounced, in every 
patient. There is a well accepted underlying disease, e.g., terminal liver failure with 
impaired hemostasis. OLT represents an "exogenous" trigger resulting in increased 
fibrin formation, bleeding and the risk of multi-organ failure. Therefore the main 
criteria for the diagnosis of DIC are fulfilled. Our investigations provide evidence for 
a hypothetical pathophysiological pattern (Fig. 6) leading to increased bleeding 
tendency in the reperfusion phase in OLT and are offering the opportunity to study 
different therapeutic options to ameliorate the clinical picture. 
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